Sunday, February 22, 2026
22.2 C
Bengaluru

Is Your Field Force Optimised to Make the Most of Market Growth in Metros?

Summary of Performance of Top 30 Metros in IPM – Dec’24

Overall Market Performance
• The top 30 metros in India contributed 34% to the total IPM (Indian Pharmaceutical Market) sales for MAT (Moving Annual Total) Dec’24.
• These cities grew at a rate of 8.5%, slightly higher than the overall IPM growth of 7.6%.
• The total market value of these 30 metros increased from ₹71,831 Cr (Dec’23) to ₹77,929 Cr (Dec’24), showing a ₹6,098 Cr increase.

Fastest-Growing Markets
• Top 5 fastest-growing metros:
1. Pune (15%)
2. Agra (14%)
3. Lucknow (13%)
4. Nashik (13%)
5. Delhi (12.5%)
• Among the six mega metros, Delhi grew the fastest at 12.5%, followed by Chennai (11.6%) and Hyderabad (10.5%).

Growth Trends & Insights
• 13 out of 30 metros grew faster than the IPM growth rate (7.6%), while 17 metros grew at or below the IPM growth rate.
• Cities like Delhi, Hyderabad, Bangalore, and Chennai remain dominant in total market value, with Delhi leading at ₹10,756 Cr.
• Smaller cities like Bhopal (12%) and Nashik (13%) showed strong growth, indicating increasing pharmaceutical demand in Tier-2 cities.

Conclusion

The Indian pharmaceutical market continues to grow robustly, especially in urban centers. While mega metros remain strong contributors, smaller cities like Lucknow, Pune, and Agra are emerging as high-growth markets. The steady expansion of IPM in these metros suggests increasing healthcare accessibility and demand for pharmaceutical products in urban India.

Hot this week

Aflibercept: When Originators Stop Fighting and Start Licensing

When Regeneron Pharmaceuticals and Bayer AG signed a licensing...

India’s Pharma Renaissance: Private Equity at the Helm

Indian pharmaceuticals have long been known as the “pharmacy...

The ₹5 Snack SKU: A Silent Indian Metabolic Crisis

Executive Summary — The Paradox of Scale In the annals...

Sleep Apnea: Apnimed Pill to Replace CPAP Machine?

In India, where urban sleep debt is rising, obesity...

Why the World Still Doesn’t Celebrate Antibiotic Breakthroughs llike Zaynich

When a new cancer drug shows promise, it trends...

Topics

Aflibercept: When Originators Stop Fighting and Start Licensing

When Regeneron Pharmaceuticals and Bayer AG signed a licensing...

India’s Pharma Renaissance: Private Equity at the Helm

Indian pharmaceuticals have long been known as the “pharmacy...

The ₹5 Snack SKU: A Silent Indian Metabolic Crisis

Executive Summary — The Paradox of Scale In the annals...

Sleep Apnea: Apnimed Pill to Replace CPAP Machine?

In India, where urban sleep debt is rising, obesity...

From Overuse to Overreaction: Recalibrating India’s C-Section Debate

India’s caesarean section debate is drifting toward polarisation. On one...

Sanofi’s Decision not to Renew Paul Hudson as CEO Marks a Structural Shift

In big pharma, leadership changes are rarely impulsive. They...

THE ENCUBE ETHICALS PLAYBOOK: FROM GOA WORKSHOP TO $2BN+ GLOBAL DEAL

How a niche Indian topicals manufacturer outgrew its CDMO...
spot_img

Related Articles

spot_imgspot_img